Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study Evaluating the Efficacy and Safety of Weekly Paclitaxel or Nab-Paclitaxel Combined With Pembrolizumab and Mirabegron in Patients With Recurrent Ovarian Cancer

NCT07261683 is registered in ClinicalTrials.gov with Obstetrics & Gynecology Hospital of Fudan University as lead sponsor.

NCT NCT07261683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07261683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study Evaluating the Efficacy and Safety of Weekly Paclitaxel or Nab-Paclitaxel Combined With Pembrolizumab and Mirabegron in Patients With Recurrent Ovarian Cancer
Lead sponsor
Obstetrics & Gynecology Hospital of Fudan University
Phase
Phase 2
Overall status
Recruiting
Start date
December 31, 2025
Completion date
November 30, 2028
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

immunotherapy, ovarian cancer, pembrolizumab